Published in Cancer Weekly, February 8th, 2005
Each unit consists of 1 common share and one-half of 1 common share purchase warrant. Each whole warrant will entitle the holder to purchase 1 additional common share of the company at a price of $0.60 for a period of 24 months from the closing date of the private placement.
The proceeds will be used to fund the on-going development of the company's cellular-engineering and cell-therapy programs and for general working capital purposes.
The company expects this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.